NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.
You may also be interested in...
UK’s NICE Proposes Lucentis Dose-Capping Approach To Coverage For Wet AMD
Agency releases new draft in response to criticism of an earlier recommendation that would limit payment to treatment in the second affected eye.
UK’s NICE Proposes Lucentis Dose-Capping Approach To Coverage For Wet AMD
Agency releases new draft in response to criticism of an earlier recommendation that would limit payment to treatment in the second affected eye.
Lucentis SAILOR Trial Hits Choppy Water
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: